Skip to main content
Top
Published in: Surgery Today 12/2017

01-12-2017 | Original Article

Adherence to an elemental diet for preventing postoperative recurrence of Crohn’s disease

Authors: Nobuyoshi Ohara, Tsunekazu Mizushima, Hideki Iijima, Hidekazu Takahashi, Satoshi Hiyama, Naotsugu Haraguchi, Takahiro Inoue, Junichi Nishimura, Shinichiro Shinzaki, Taishi Hata, Chu Matsuda, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori

Published in: Surgery Today | Issue 12/2017

Login to get access

Abstract

Purpose

An elemental diet (ED) can suppress inflammation in patients with Crohn’s disease (CD); however, adherence to this diet is difficult. We examined the correlation between ED adherence and the postoperative recurrence of CD.

Methods

The subjects of this study were 38 patients who underwent intestinal resection with anastomosis. We defined ED adherence as consuming the average daily ED dose (≥900 kcal/day) for 2 years after surgery. Patients who did not adhere to the ED were allocated to the non-ED group. We diagnosed symptomatic recurrence using the CD activity index and endoscopic recurrence using the Rutgeerts’ score.

Results

The ED and non-ED groups comprised 21 and 17 patients, respectively, with ED adherence of 55.3% (21/38). At the initial endoscopy, symptomatic and endoscopic recurrence rates were 4.8 and 14.3%, respectively, in the ED group, and 23.5 and 41.2%, respectively, in the non-ED group (P = 0.152 and P = 0.078, respectively). The overall symptomatic recurrence-free duration was significantly longer than the endoscopic recurrence-free duration (P = 0.022). Symptomatic and endoscopic recurrence-free durations were longer in the ED group than in the non-ED group (P = 0.003 and P = 0.021, respectively), and ED adherence was a prognostic factor for endoscopic recurrence (HR = 2.777, 95% CI = 1.036–8.767, P = 0.042).

Conclusion

Maintaining ED adherence for 2 years after surgery improved the symptomatic and endoscopic recurrence-free durations.
Literature
1.
go back to reference Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–25 (Epub 2010/11/26).CrossRefPubMedPubMedCentral Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–25 (Epub 2010/11/26).CrossRefPubMedPubMedCentral
2.
go back to reference Mitsuyama K, Sata M. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opin Ther Targets. 2008;12(3):301–12 (Epub 2008/02/14).CrossRefPubMed Mitsuyama K, Sata M. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opin Ther Targets. 2008;12(3):301–12 (Epub 2008/02/14).CrossRefPubMed
4.
go back to reference Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8(4):244–50 (Epub 2002/07/20).CrossRefPubMed Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8(4):244–50 (Epub 2002/07/20).CrossRefPubMed
5.
go back to reference Chen M, Yi F, Zhou F, Huang M, Li J, Yan W, et al. Risk factors for initial surgery in patients with Crohn’s disease in Central China. Surg Today. 2015;45(8):1002–8 (Epub 2014/12/20).CrossRefPubMed Chen M, Yi F, Zhou F, Huang M, Li J, Yan W, et al. Risk factors for initial surgery in patients with Crohn’s disease in Central China. Surg Today. 2015;45(8):1002–8 (Epub 2014/12/20).CrossRefPubMed
6.
go back to reference Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn’s disease—evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25(1):3–12 (Epub 2007/01/19).PubMed Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn’s disease—evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25(1):3–12 (Epub 2007/01/19).PubMed
7.
go back to reference Williams JG, Wong WD, Rothenberger DA, Goldberg SM. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78(1):10–9 (Epub 1991/01/01).CrossRefPubMed Williams JG, Wong WD, Rothenberger DA, Goldberg SM. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78(1):10–9 (Epub 1991/01/01).CrossRefPubMed
8.
go back to reference Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–63 (Epub 1990/10/01).CrossRefPubMed Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–63 (Epub 1990/10/01).CrossRefPubMed
9.
go back to reference Terdiman JP. Prevention of postoperative recurrence in Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(6):616–20 (Epub 2007/10/31).CrossRefPubMed Terdiman JP. Prevention of postoperative recurrence in Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(6):616–20 (Epub 2007/10/31).CrossRefPubMed
10.
go back to reference Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113(5):1465–73 (Epub 1997/11/14).CrossRefPubMed Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113(5):1465–73 (Epub 1997/11/14).CrossRefPubMed
11.
go back to reference Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:Cd000067 (Epub 2000/05/05). Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:Cd000067 (Epub 2000/05/05).
12.
go back to reference Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s disease. Aliment Pharmacol Ther. 2008;27(1):11–8 (Epub 2007/10/09).CrossRefPubMed Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s disease. Aliment Pharmacol Ther. 2008;27(1):11–8 (Epub 2007/10/09).CrossRefPubMed
13.
go back to reference Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761–9 (Epub 1999/09/29).CrossRefPubMed Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761–9 (Epub 1999/09/29).CrossRefPubMed
14.
go back to reference Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333–40 (Epub 2006/10/25).CrossRefPubMed Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333–40 (Epub 2006/10/25).CrossRefPubMed
15.
go back to reference Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–21 (Epub 1995/06/01).CrossRefPubMed Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–21 (Epub 1995/06/01).CrossRefPubMed
16.
go back to reference Araki T, Uchida K, Okita Y, Fujikawa H, Inoue M, Ohi M, et al. Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case–control study. Surg Today. 2014;44(2):291–6 (Epub 2013/03/07).CrossRefPubMed Araki T, Uchida K, Okita Y, Fujikawa H, Inoue M, Ohi M, et al. Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case–control study. Surg Today. 2014;44(2):291–6 (Epub 2013/03/07).CrossRefPubMed
17.
go back to reference Sumi R, Nakajima K, Iijima H, Wasa M, Shinzaki S, Nezu R, et al. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn’s disease. Surg Today. 2016;46(8):922–9 (Epub 2015/10/07).CrossRefPubMed Sumi R, Nakajima K, Iijima H, Wasa M, Shinzaki S, Nezu R, et al. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn’s disease. Surg Today. 2016;46(8):922–9 (Epub 2015/10/07).CrossRefPubMed
18.
go back to reference Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9 (Epub 2002/06/06).CrossRefPubMed Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9 (Epub 2002/06/06).CrossRefPubMed
19.
go back to reference Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25 (Epub 2005/11/04).CrossRefPubMed Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25 (Epub 2005/11/04).CrossRefPubMed
20.
go back to reference Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–83 (Epub 2007/05/09).CrossRefPubMed Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–83 (Epub 2007/05/09).CrossRefPubMed
21.
go back to reference Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–79 (Epub 2004/11/13).CrossRefPubMed Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–79 (Epub 2004/11/13).CrossRefPubMed
22.
go back to reference Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn’s disease. J Gastroenterol. 1995;30(Suppl 8):83–7 (Epub 1995/11/01).PubMed Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn’s disease. J Gastroenterol. 1995;30(Suppl 8):83–7 (Epub 1995/11/01).PubMed
23.
go back to reference Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995;30(3):322–9 (Epub 1995/06/01).CrossRefPubMed Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995;30(3):322–9 (Epub 1995/06/01).CrossRefPubMed
24.
go back to reference Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 2007;25(1):67–72 (Epub 2007/01/19).CrossRefPubMed Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 2007;25(1):67–72 (Epub 2007/01/19).CrossRefPubMed
25.
go back to reference Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T, et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology. 2009;136(2):564-74.e2 (Epub 2008/11/26).CrossRefPubMed Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T, et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology. 2009;136(2):564-74.e2 (Epub 2008/11/26).CrossRefPubMed
26.
go back to reference Kishi D, Takahashi I, Kai Y, Tamagawa H, Iijima H, Obunai S, et al. Alteration of V beta usage and cytokine production of CD4 + TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. J Immunol. 2000;165(10):5891–9 (Epub 2000/11/09).CrossRefPubMed Kishi D, Takahashi I, Kai Y, Tamagawa H, Iijima H, Obunai S, et al. Alteration of V beta usage and cytokine production of CD4 + TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. J Immunol. 2000;165(10):5891–9 (Epub 2000/11/09).CrossRefPubMed
27.
go back to reference Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13(12):1493–501 (Epub 2007/09/20).CrossRefPubMed Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13(12):1493–501 (Epub 2007/09/20).CrossRefPubMed
28.
go back to reference Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441-50.e1 (Epub 2008/12/27).CrossRef Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441-50.e1 (Epub 2008/12/27).CrossRef
Metadata
Title
Adherence to an elemental diet for preventing postoperative recurrence of Crohn’s disease
Authors
Nobuyoshi Ohara
Tsunekazu Mizushima
Hideki Iijima
Hidekazu Takahashi
Satoshi Hiyama
Naotsugu Haraguchi
Takahiro Inoue
Junichi Nishimura
Shinichiro Shinzaki
Taishi Hata
Chu Matsuda
Hirofumi Yamamoto
Yuichiro Doki
Masaki Mori
Publication date
01-12-2017
Publisher
Springer Japan
Published in
Surgery Today / Issue 12/2017
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-017-1543-5

Other articles of this Issue 12/2017

Surgery Today 12/2017 Go to the issue